DUBLIN, June 30, 2021 /PRNewswire/ — The “Investigation Report on China’s Enteral Nutrition Market 2021-2025″ report has been added to ResearchAndMarkets.com’s providing.
According to the evaluation, the gross sales worth of Enteral Nutrition in China has grown steadily yr by yr from 2016 to 2019. In 2020, because of the influence of the COVID-19 epidemic on the hospital’s general analysis and remedy providers, the gross sales worth of Enteral Nutrition in China fell barely, reached CNY1.155 billion in 2020. The CAGR of the gross sales worth of Enteral Nutrition is about 6.5% from 2016 to 2020 in China.
By 2020, along with Niudi Xiya Pharmaceutical (Wuxi) Co.,ltd., there are Fresenius Kabi Deutschland GmbH, Fresenius Kabi Huarui Pharmaceutical Co., Ltd., Abbott Laboratories BV, and Milupa GmnH & Co KG and different 8 producers in China’s Enteral Nutrition market.
The analyst expects that with the efficient reduction of the COVID-19 epidemic, the gross sales of Enteral Nutrition within the Chinese market may have a restorative progress from 2021 to 2025. In addition, Enteral Nutrition is extensively used clinically. With the advance and popularization of medical providers in China, the demand for Enteral Nutrition will proceed to extend, so the gross sales of Enteral Nutrition in China will preserve a rising pattern.
Topics Covered:
- The influence of COVID-19 on China’s Enteral Nutrition market
- Sales worth of China’s Enteral Nutrition 2016-2020
- Competitive panorama of China’s Enteral Nutrition market
- Prices of Enteral Nutrition in China
- Prices of Enteral Nutrition in China by areas and producers
- Analysis of things affecting the event of China’s Enteral Nutrition market
- Prospect of China’s Enteral Nutrition market from 2021 to 2025
Key Topics Covered:
1 Relevant Concepts of Enteral Nutrition
1.1 Indications for Enteral Nutrition
1.2 Development of Enteral Nutrition in China
1.3 Governmental Approval of Enteral Nutrition in China
1.4 The Impact of COVID-19 on Enteral Nutrition gross sales in China
2 Sales of Enteral Nutrition in China, 2016-2020
2.1 Sales Value of Enteral Nutrition
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Enteral Nutrition
2.3 Sales of Enteral Nutrition by Dosage Form in China, 2016-2020
2.3.1 Suspension
2.3.2 Oral Powder
2.3.3 Oral Emulsion
3 Analysis of Major Enteral Nutrition Manufacturers in China, 2016-2020
3.1 Analysis of Market Share of Major Enteral Nutrition Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales quantity
3.2 Niudi Xiya Pharmaceutical (Wuxi) Co.,ltd.
3.2.1 Enterprise Profile
3.2.2 Sales of PEPTISON (Niudi Xiya Pharmaceutical (Wuxi) Co.,ltd.’s Enteral Nutrition) in China
3.3 Fresenius Kabi Deutschland GmbH
3.4 Fresenius Kabi Huarui Pharmaceutical Co., Ltd.
3.5 Abbott Laboratories BV
3.6 Milupa GmnH & Co KG
4 Prices of Enteral Nutrition for Different Manufacturers in China, 2020-2021
4.1 Niudi Xiya Pharmaceutical (Wuxi) Co.,ltd. (PEPTISON)
4.2 Fresenius Kabi Deutschland GmbH (FRESUBIN)
4.3 Fresenius Kabi Huarui Pharmaceutical Co., Ltd. (FRESUBIN DIABETES, FRESUBIN 750MCT, Ruineng)
4.4 Abbott Laboratories BV (JEVITY)
4.5 Milupa GmnH & Co KG(NUTRISON)
5 Prospect of Chinese Enteral Nutrition Market, 2021-2025
5.1 Influential Factors of Chinese Enteral Nutrition Market Development
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
For extra details about this report go to https://www.researchandmarkets.com/r/85mgfv
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outdoors U.S.): +353-1-481-1716
SOURCE Research and Markets
